Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1771 to 1785 of 9022 results

  1. Selinexor with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 to 4 treatment lines in people who have not had pomalidomide [ID6705]

    Awaiting development Reference number: GID-TA11938 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Awaiting development Reference number: GID-TA11917 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. DB-OTO for Hearing loss [ID6728]

    Awaiting development Reference number: GID-TA11911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]

    Awaiting development Reference number: GID-TA11978 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Bictegravir–lenacapavir for treating HIV-1 [ID6744]

    Awaiting development Reference number: GID-TA11970 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]

    Awaiting development Reference number: GID-TA11964 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TSID10723]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Natural Cycles for monitoring fertility

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation